Rare disease brands face a different commercial reality than mass market therapies. Patient populations are small, treatment centers are specialized, and every HCP relationship matters.
Building the right commercial team is not just about headcount. It is about choosing the right roles for the right stage of the product journey.
Two roles sit at the center of this strategy. Medical Science Liaisons, known as MSLs, and field sales representatives. Understanding how they differ, and how they work together, is essential for a successful rare disease launch.
What Is Rare Disease Commercialization
Rare disease commercialization is the process of bringing a therapy to market when the patient population is small and highly specialized. Unlike primary care launches, rare disease brands often deal with:
- A limited number of treating physicians nationwide
- Complex reimbursement and payer navigation requirements
- High scientific and clinical education needs
- Long diagnostic journeys before a patient even reaches treatment
Because the target audience is so narrow, every interaction with a physician needs to count. This is where the roles of MSL and field sales rep become critical, and distinct.
What Does an MSL Do
A Medical Science Liaison is a scientific expert who engages with physicians, key opinion leaders, and academic centers on clinical and scientific topics.
MSLs typically hold advanced degrees such as a PharmD or PhD. Their role is medical and educational, not promotional.
Core MSL responsibilities include:
- Discussing clinical trial data and mechanism of action in depth
- Answering unsolicited medical questions from physicians
- Building relationships with key opinion leaders, also known as KOLs
- Supporting investigator initiated research and publications
- Gathering field insights to inform clinical and medical strategy
MSLs operate independently from the commercial and sales organization. This separation protects the scientific integrity of their conversations and keeps them compliant with regulatory guidelines.
What Does a Field Sales Rep Do
A field sales representative, sometimes called a pharmaceutical sales rep, focuses on driving prescribing behavior through approved promotional messaging.
In rare disease settings, field reps still need strong clinical fluency, but their conversations are commercial in nature. Core responsibilities include:
- Presenting approved product information to prescribers
- Educating providers on patient support programs and access resources
- Managing territory coverage and call planning
- Building long term relationships with high volume specialists
- Reporting field activity and prescribing trends back to the brand team
Field reps are measured on commercial outcomes such as prescription growth. MSLs are measured on scientific engagement and medical strategy contributions.
MSL vs Field Sales: Key Differences
The table below breaks down how these two roles differ across a rare disease launch.
- Purpose MSLs educate. Field reps promote.
- Compliance Boundaries MSLs can discuss off label data and unpublished research when appropriate. Field reps must stay within approved labeling and promotional materials.
- Reporting Structure MSLs typically report through medical affairs. Field reps report through commercial or sales leadership.
- Timing in the Launch MSLs often engage before and during launch to build scientific credibility. Field reps ramp up around and after approval to drive prescribing volume.
- Relationship Type MSLs build peer to peer scientific relationships. Field reps build commercial partnerships focused on patient access and support.
Why Rare Disease Brands Need Both Roles
Some companies assume they can rely on one function alone. In rare diseases, that rarely works.
Physicians treating rare conditions want deep scientific context before they consider a new therapy. That is the MSL's job. But once a physician is ready to prescribe, they need practical support around access, dosing logistics, and patient programs. That is where field sales adds value.
Used together, these roles create a complete commercial motion.
- MSLs build early trust and scientific credibility with treating physicians
- Field reps convert that credibility into confident, supported prescribing
- Both roles feed insights back into the brand's overall market strategy
- Coordinated messaging avoids confusion or compliance risk in the field
Building the Right Team Structure for Your Rare Disease Launch
The right ratio of MSLs to field reps depends on the size of your target physician universe and the complexity of your therapy.
Smaller, ultra rare indications may need a higher ratio of MSLs relative to field reps, since scientific education carries more weight than volume based selling. Broader specialty conditions may support a larger field sales presence alongside a focused MSL team.
At Promoveo Health, our Specialty and Key Account model is built specifically for this kind of complexity. It combines KAM and MSL integration with payer navigation and institutional contracting support, giving rare disease brands a coordinated team rather than disconnected functions.
Our Biotech Contract Sales programs are designed for early stage and rare disease brands that need clinical fluency built into every rep from day one. Reps are matched to therapy areas based on relevant experience, not assigned at random.
Why Trust Promoveo Health With Rare Disease Commercialization
Rare disease launches leave little room for error. A few reasons pharma and biotech brands trust us with this level of complexity:
- We deploy field ready teams in as few as three weeks
- Our rep retention rate sits at 95 percent, supporting long term physician relationships
- We cover more than 20 therapeutic areas, including rare and orphan disease categories
- One of our rare disease programs reached 91 percent of 800 target HCPs nationally within 60 days of launch
- Our Specialty and Key Account model pairs MSL integration with payer and institutional contracting expertise
Frequently Asked Questions
What is the main difference between an MSL and a field sales rep?
An MSL focuses on scientific education and peer to peer engagement with physicians. A field sales rep focuses on approved promotional messaging that drives prescribing.
Can an MSL and a field rep visit the same physician?
Yes, but their conversations serve different purposes. MSLs discuss science and clinical data, while field reps discuss approved product information and patient support resources.
Do rare disease brands need MSLs before launch?
In most cases, yes. Engaging KOLs and treating physicians with scientific data before launch helps build credibility that supports adoption once the product is approved.
How many MSLs does a rare disease brand typically need?
This depends on the size of the target physician population. Smaller, highly specialized indications often need fewer MSLs covering a defined KOL list, while broader conditions may require wider coverage.
Does Promoveo Health provide both MSL and field sales support?
Yes. Our Specialty and Key Account model integrates KAM and MSL support alongside field sales and payer navigation for rare disease and specialty brands.
How quickly can a rare disease commercial team be deployed?
Most Promoveo Health programs deploy in three to five weeks depending on the engagement model and target HCP universe.
Ready to Build Your Rare Disease Commercial Team
Rare disease success depends on getting scientific and commercial roles right from day one. The correct mix of MSL and field sales expertise can shape how quickly patients get access to the therapies they need.
Contact Promoveo Health today to design a rare disease commercialization team built around your therapy, your physicians, and your launch timeline.